Trial studying safety and effects for Solid Tumor
Official title A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
ClinicalTrials.gov ID: NCT04300556
What this study is testing
What is Farletuzumab ecteribulin (MORAb-202)?
an investigational intravenous antibody‑drug conjugate being studied as a potential treatment for solid tumors such as ovarian, endometrial, non‑small cell lung, and triple‑negative breast cancers is designed to bind the folate‑receptor alpha on cancer cells and deliver the chemotherapy agent eribulin directly to those cells
Also referred to as MORAb-202.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find a safe dose of MORAb‑202 and see early signs it can shrink tumors in these cancers.
- Who it's for
- Adults who have ovarian cancer, endometrial cancer, non‑small cell lung cancer, or triple‑negative breast cancer.
- What's involved
- Participants receive an IV infusion of MORAb‑202 every 21 days, may take a short course of oral steroids after each dose, and some may also receive the oral drug lenvatinib. Regular clinic visits, blood tests and imaging scans are done to monitor safety and tumor response.
- Time commitment
- Treatment cycles are every 3 weeks, with clinic visits for each infusion and periodic follow‑up visits for several months.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Aged \>=18 years
- TNBC: Histologically confirmed diagnosis of metastatic TNBC (that is, estrogen receptor (ER) negative/progesterone receptor negative/ human epidermal...
- NSCLC adenocarcinoma: Histologically or cytologically confirmed metastatic NSCLC adenocarcinoma: participants who have failed previous treatment for...
- EC: Histologically confirmed diagnosis of advanced, recurrent or metastatic EC.
- platinum-resistant disease (defined as progression within 6 months after the last dose of at least 4 cycles of the last platinum containing...
You likely can't join if
- Participants with endometrial leiomyosarcoma, endometrial stromal sarcoma or other soft tissue sarcoma histology.
- Participants who received previous treatment with any folate receptor targeting agents, except for mirvetuximab soravtansine in the setting of FRA...
- Participants with platinum refractory ovarian cancer (defined as disease progression during the initial platinum-based chemotherapy treatment).
- Currently enrolled in another clinical study or used any investigational drug or device, which in the opinion of the Sponsor may interfere with the...
- Participants with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of...
- Diagnosed with meningeal carcinomatosis.
See the full eligibility criteria
Who can join
- Aged \>=18 years
- TNBC: Histologically confirmed diagnosis of metastatic TNBC (that is, estrogen receptor (ER) negative/progesterone receptor negative/ human epidermal growth factor receptor 2 (HER2) negative (defined as...
- NSCLC adenocarcinoma: Histologically or cytologically confirmed metastatic NSCLC adenocarcinoma: participants who have failed previous treatment for metastatic disease, are not indicated or failed epidermal growth...
- EC: Histologically confirmed diagnosis of advanced, recurrent or metastatic EC. Relapsed or failure of at least one platinum-based regimen or one immunotherapy-based regimen.
- platinum-resistant disease (defined as progression within 6 months after the last dose of at least 4 cycles of the last platinum containing chemotherapy regimen)
- For participant with 1 line of platinum-containing therapy: progression greater than (\>) 1 month and less than or equal to (\<=) 6 months after the last dose of the first platinum-containing chemotherapy regimen (of at...
- For participant with 2-3 lines of platinum-containing therapy: progression during or within 6 months after the last dose of the 2nd or 3rd platinum-containing chemotherapy regimen.
- Have received up to 3 prior lines of systemic therapy and for whom single-agent therapy is appropriate as the next line of therapy.
- Neoadjuvant plus/minus (±) adjuvant will be considered 1 line of therapy.
- Maintenance therapy (example, bevacizumab, PARP inhibitors) will be considered part of the preceding line of therapy (will not be counted as an independent line of therapy).
- Hormonal therapy will be counted as a separate line of therapy unless it was given as maintenance.
- Participants must have histologically confirmed diagnosis of advanced, recurrent, or metastatic EC.
- Note: There is no restriction regarding prior hormonal therapy.
- Available tumor tissue for FRA expression percent (%) by IHC analysis as assessed at a central laboratory. There is no minimum requirement for FRA expression (%).
- Radiological disease progression on or after the most recent therapy by investigator assessment.
- At least one lesion of \>1.0 centimeter (cm) in long axis diameter for non-lymph nodes or \>1.5 cm in short axis diameter for lymph nodes that is serially measurable according to Response Evaluation Criteria in Solid...
- Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show evidence of PD based on RECIST 1.1 to be deemed a target lesion.
- ECOG PS of 0 or 1.
- Participants who are expected to survive a minimum of 3 months after the first administration of the study drug.
- Adequate renal function as evidenced by serum creatinine less than or equal to (\ =50 milliliter per (mL) /minute according to a 12 or 24 hour urine collection.
- Absolute neutrophil count (ANC) \>=1.0\ 10\^9 per liter (/L) (MORAb-202 monotherapy cohorts only)
- ANC \>=1.5\ 10\^9/L (MORAb-202 plus lenvatinib cohorts)
- Hemoglobin (Hgb) \>=9.0 gram per deciliter (g/dL)
- Platelet count \>=75\ 10\^9/L Growth factors or transfusions as per institutional practice, are allowed if needed to achieve the above values.
- Total bilirubin \<=1.5\ upper limit of normal (ULN) except for unconjugated hyperbilirubinemia (example, Gilbert's syndrome)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \<=3\ ULN (in the case of liver metastases \<=5\ ULN).
- Albumin \>3.0 g/dL.
- Prior chemotherapy, surgical therapy, radiation therapy: \>3 weeks. Prior chest radiotherapy or pneumonectomy is an exclusion.
- Antibody and other biologic therapeutic agents: \>=4 weeks.
- Endocrine therapy or, small-molecule targeted therapy: \>2 weeks.
- Immunotherapy \>=4 weeks.
- Participants with a history of deep vein thrombosis (DVT) within 3 months of enrollment must be on a stable dose of anticoagulation as demonstrated by appropriate laboratory parameters (depending on the anticoagulant...
- Participants at risk for DVT secondary to central venous catheters or with past medical history of DVT or clinical symptoms suggestive of DVT must have venous Doppler ultrasonography to rule out DVT during the screening...
- If a participant has undergone major surgery, the participant must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.
- Resolution of anticancer therapy-related or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy (Grade \ =9.0 g/dL), and alopecia (any grade).
- Participant must be willing and able to comply with all aspects of the protocol.
- Participant must provide written informed consent prior to any study-specific screening procedures.
- For cohorts where MORAb-202 is used in combination with lenvatinib: Has adequately controlled blood pressure (BP) with or without antihypertensive medications, defined as BP \<=150/90 millimeter of mercury (mm Hg) and...
What rules you out
- Participants with endometrial leiomyosarcoma, endometrial stromal sarcoma or other soft tissue sarcoma histology.
- Participants who received previous treatment with any folate receptor targeting agents, except for mirvetuximab soravtansine in the setting of FRA \>=75%.
- Participants with platinum refractory ovarian cancer (defined as disease progression during the initial platinum-based chemotherapy treatment).
- Currently enrolled in another clinical study or used any investigational drug or device, which in the opinion of the Sponsor may interfere with the study treatment, within the past 28 days or 5 times the half-life...
- Participants with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 2 weeks before starting...
- Diagnosed with meningeal carcinomatosis.
- Any other invasive malignancy that required treatment (other than definitive surgery) or has shown evidence of recurrence/progression (except for non-melanoma skin cancer, or histologically confirmed complete excision...
- Significant cardiovascular impairment. History within 6 months prior to the first dose of study drug of: congestive heart failure greater than New York Heart Association (NYHA) Class II); unstable angina
- Clinically significant ECG abnormality, including marked prolonged baseline QT as corrected using Fridericia's formula (QTcF) (repeated demonstration of a QTcF interval \>500 milliseconds [ms]).
- Known to be Human Immunodeficiency Virus (HIV) positive. Testing at entry not required.
- Active viral hepatitis (B or C as demonstrated by positive serology). Testing at entry if there are no symptoms or history is not required unless as per local requirements.
- Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a positive beta human chorionic gonadotropin [ß-hCG] or human chorionic gonadotropin [hCG]) with a minimum sensitivity of 25...
- Females of childbearing potential who
- total abstinence (if it is their preferred and usual lifestyle)\
- an intrauterine device or intrauterine hormone-releasing system (IUS)
- a contraceptive implant
- combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) or progestogen-only hormonal contraception associated with inhibition of...
- bilateral tubal occlusion
- have a vasectomized partner with confirmed azoospermia
- do not agree to use a highly effective method of contraception (as described above) throughout the entire study period and for 7 months (5\ half-life plus 180 days) after study drug discontinuation.
- For Dose-Escalation only: Males who have not had a successful vasectomy (confirmed azoospermia) or they and their female partners do not meet the criteria above (that is, not of childbearing potential or practicing...
- Pulmonary Function Test (PFT) abnormalities: FEV1/FVC \<0.7, FEV1 or FVC \<80%, DLCO \<80% or less than the lower limit of normal according to local institutional standards.
- Current ILD/pneumonitis, or ILD/pneumonitis is suspected at Screening or history of interstitial lung disease (ILD)/pneumonitis of any severity including ILD/pneumonitis from prior anticancer therapy.
- Current infectious pneumonia, history of viral pneumonia (including COVID-19-related infection) with evidence of persistent radiologic abnormalities.
- Lung-specific clinically significant illnesses including, but not limited to any underlying pulmonary disorder (example, pulmonary embolism), asthma, chronic obstructive pulmonary disease (COPD), and restrictive lung...
- Clinically significant pleural or pericardial effusion requiring drainage or ascites requiring peritoneal shunt.
- Prior pneumonectomy.
- History of chest radiotherapy. Participants with history of chest wall radiation (example, history of breast cancer) may be permitted if chest wall radiation is documented \> 2 years before starting study treatment.
- Any autoimmune, connective tissue, or inflammatory disorders (example, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis, etc) where there is documented (or suspicion of) pulmonary involvement.
- A known history of active TB (bacillus tuberculosis).
- Scheduled for surgery during the study, other than minor surgery which would not delay study treatment.
- An active clinically significant (in the opinion of the Investigator) infection requiring systemic therapy within 2 weeks prior to the first dose of study drug.
- Administration of a live, attenuated vaccine within 4 weeks prior to the first dose of study drug, or anticipation that such a live attenuated vaccine will be required during the study.
- Any prior hypersensitivity to monoclonal antibodies or contraindication to the receipt of corticosteroids or any of the excipients (investigators should refer to the prescribing information for the selected...
- Known intolerance to either of the components of the study drug.
- Any medical or other condition which, in the opinion of the investigator would preclude the participants participation in the clinical study.
- Receiving any medication prohibited in combination with the study treatment(s) as described in the product label for eribulin, unless medication was stopped within 7 days prior to enrollment.
- \>1+ proteinuria on dipstick, 24-hour urine protein is \>=1 gram.
- Gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib.
- Unable to take oral medication.
- Major surgery within 3 weeks before the first dose of study treatment. Note: adequate wound healing after major surgery must be assessed clinically and independent of time elapsed for eligibility.
- Serious nonhealing wound, ulcer or bone fracture.
- Pre-existing Grade \>=3 gastrointestinal (GI) or non-GI fistula.
- Radiographic evidence of major blood vessel invasion/infiltration. The degree of tumor invasion / infiltration of major blood vessels should be considered because of the potential risk of severe hemorrhage associated...
The study team makes the final eligibility decision.
Where it is enrolling
- Palo Alto, California, United States
- Tampa, Florida, United States
- Augusta, Georgia, United States
- Chicago, Illinois, United States
- New York, New York, United States
- Chuo-ku, Tokyo, Japan
- Koto-ku, Tokyo, Japan
- Badalona, Barcelona, Spain
- Barcelona, Spain
- Valencia, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Palo Alto, California, United States; Tampa, Florida, United States; Augusta, Georgia, United States; Chicago, Illinois, United States; New York, New York, United States; Chuo-ku, Tokyo, Japan and 4 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.